2021 Q1 Form 10-Q Financial Statement

#000162828021009446 Filed on May 07, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.128M $1.412M
YoY Change -20.12% 18.62%
% of Gross Profit
Research & Development $609.7K $799.6K
YoY Change -23.76% 149.88%
% of Gross Profit
Depreciation & Amortization $938.00 $365.00
YoY Change 156.99%
% of Gross Profit
Operating Expenses $1.737M $2.211M
YoY Change -21.43% 45.47%
Operating Profit -$1.737M -$2.211M
YoY Change -21.43%
Interest Expense $184.9K $166.4K
YoY Change 11.15% -101.25%
% of Operating Profit
Other Income/Expense, Net -$423.3K -$130.5K
YoY Change 224.45% -99.02%
Pretax Income -$2.161M -$2.342M
YoY Change -7.74% -84.15%
Income Tax
% Of Pretax Income
Net Earnings -$2.161M -$2.342M
YoY Change -7.74% -84.15%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 336.9M shares 182.3M shares
Diluted Shares Outstanding 336.9M shares 183.7M shares

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.152M $563.9K
YoY Change 813.78% -87.21%
Cash & Equivalents $5.152M $563.9K
Short-Term Investments
Other Short-Term Assets $229.2K $107.5K
YoY Change 113.19% -65.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.382M $671.4K
YoY Change 701.6% -85.78%
LONG-TERM ASSETS
Property, Plant & Equipment $17.10K $1.620K
YoY Change 955.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $17.10K $1.620K
YoY Change 955.49%
TOTAL ASSETS
Total Short-Term Assets $5.382M $671.4K
Total Long-Term Assets $17.10K $1.620K
Total Assets $5.399M $673.0K
YoY Change 702.21% -85.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $499.9K $978.2K
YoY Change -48.9% 475.39%
Accrued Expenses $175.1K $35.65K
YoY Change 391.29% -83.03%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $103.5K
YoY Change
Total Short-Term Liabilities $1.384M $1.667M
YoY Change -16.97% -94.19%
LONG-TERM LIABILITIES
Long-Term Debt $1.536M $517.8K
YoY Change 196.61% -82.21%
Other Long-Term Liabilities $190.9K
YoY Change -80.12%
Total Long-Term Liabilities $1.536M $708.7K
YoY Change 116.71% -81.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.384M $1.667M
Total Long-Term Liabilities $1.536M $708.7K
Total Liabilities $2.920M $2.376M
YoY Change 22.9% -92.71%
SHAREHOLDERS EQUITY
Retained Earnings -$40.89M
YoY Change
Common Stock $43.37M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.479M -$1.703M
YoY Change
Total Liabilities & Shareholders Equity $5.399M $673.0K
YoY Change 702.21% -85.74%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$2.161M -$2.342M
YoY Change -7.74% -84.15%
Depreciation, Depletion And Amortization $938.00 $365.00
YoY Change 156.99%
Cash From Operating Activities -$1.348M -$1.266M
YoY Change 6.47% -11.46%
INVESTING ACTIVITIES
Capital Expenditures $10.70K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.70K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $4.042M $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$1.348M -$1.266M
Cash From Investing Activities -$10.70K $0.00
Cash From Financing Activities $4.042M $0.00
Net Change In Cash $2.683M -$1.266M
YoY Change -311.91% -149.46%
FREE CASH FLOW
Cash From Operating Activities -$1.348M -$1.266M
Capital Expenditures $10.70K $0.00
Free Cash Flow -$1.359M -$1.266M
YoY Change 7.32% -11.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001516551
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
000-55136
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Skye Bioscience, Inc.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0692882
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5910 Pacific Center Blvd
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 320
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2469410 USD
CY2021Q1 dei City Area Code
CityAreaCode
949
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
480-9051
CY2021Q1 dei Security12g Title
Security12gTitle
Common Stock, par value $0.001
CY2021Q1 dei Trading Symbol
TradingSymbol
SKYE
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
371974416 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5152425 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4567 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4566 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
224608 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
190409 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
5381600 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2664385 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17099 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7341 USD
CY2021Q1 us-gaap Assets
Assets
5398699 USD
CY2020Q4 us-gaap Assets
Assets
2671726 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
499854 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
364340 USD
CY2021Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
10000 USD
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
17032 USD
CY2021Q1 embi Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
43129 USD
CY2020Q4 embi Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
44087 USD
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
131995 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
61547 USD
CY2021Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
103523 USD
CY2020Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
64062 USD
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
276917 USD
CY2020Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
450000 USD
CY2021Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1072593 USD
CY2021Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
318862 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
197564 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
38567 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1384280 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
787199 USD
CY2021Q1 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
13177 USD
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
52638 USD
CY2021Q1 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
450000 USD
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
931103 USD
CY2021Q1 us-gaap Liabilities
Liabilities
2920050 USD
CY2020Q4 us-gaap Liabilities
Liabilities
2220940 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
367641082 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
367641082 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
288074415 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
288074415 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
367641 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
288074 USD
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43005506 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38896693 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40894498 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38733981 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2478649 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5398699 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2671726 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
609656 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
799612 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1737262 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
2211208 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1127606 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1411596 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1737262 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2211208 USD
CY2021Q1 embi Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
238350 USD
CY2020Q1 embi Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-35903 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
184905 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
166355 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-423255 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-130452 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2160517 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2341660 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2341660 USD
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
336883489 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
182256966 shares
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
336883489 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
183737415 shares
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2341660 USD
CY2021Q1 us-gaap Depreciation
Depreciation
938 USD
CY2020Q1 us-gaap Depreciation
Depreciation
365 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
146580 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
64142 USD
CY2021Q1 embi Fair Value Adjustment Of Derivative Liabilities
FairValueAdjustmentOfDerivativeLiabilities
-238350 USD
CY2020Q1 embi Fair Value Adjustment Of Derivative Liabilities
FairValueAdjustmentOfDerivativeLiabilities
35903 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
135514 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
141490 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
130710 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34199 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-57290 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
807457 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-7032 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
30903 USD
CY2021Q1 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-958 USD
CY2020Q1 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
35645 USD
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
70448 USD
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-24546 USD
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
121298 USD
CY2020Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
9484 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1348088 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1266113 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10696 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10696 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
4030000 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q1 embi Proceeds From Pre Funded Warrant Exercises
ProceedsFromPreFundedWarrantExercises
11800 USD
CY2020Q1 embi Proceeds From Pre Funded Warrant Exercises
ProceedsFromPreFundedWarrantExercises
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4041800 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2683016 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1266113 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2473976 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1834515 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5156992 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
568402 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5152425 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
563864 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4567 USD
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4538 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5156992 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
568402 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
44087 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2021Q1 embi Exercise Of Warrants
ExerciseOfWarrants
0 USD
CY2020Q1 embi Exercise Of Warrants
ExerciseOfWarrants
26563 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
548058 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64142 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2341660 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1702897 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146580 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2478649 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40894498 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5152425 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets </span></div>and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity instruments, derivative liabilities, and debt with embedded features.
CY2021Q1 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
1877938 USD
CY2020Q4 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
1877938 USD
CY2021Q1 embi Research And Development Licensed Technology Costs Capitalized To Date
ResearchAndDevelopmentLicensedTechnologyCostsCapitalizedToDate
0 USD
CY2021Q1 embi Warrants Vested And Outstanding
WarrantsVestedAndOutstanding
78546668 shares
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
38567 USD
CY2021Q1 embi Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
238350 USD
CY2021Q1 embi Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
0 USD
CY2021Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
276917 USD
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
501400 USD
CY2020Q1 embi Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-35903 USD
CY2020Q1 embi Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
-26563 USD
CY2020Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
438934 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
90797 USD
CY2020Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
190882 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
410603 USD
CY2020Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
248052 USD
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.12
CY2020Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.04
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
43129 USD
CY2020Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
35645 USD
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
286 USD
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
141097 USD
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
130347 USD
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
393 USD
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
363 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
184905 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
166355 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
750469 USD
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3D
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146580 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
64142 USD

Files In Submission

Name View Source Status
0001628280-21-009446-index-headers.html Edgar Link pending
0001628280-21-009446-index.html Edgar Link pending
0001628280-21-009446.txt Edgar Link pending
0001628280-21-009446-xbrl.zip Edgar Link pending
embi-20210331.htm Edgar Link pending
embi-20210331.xsd Edgar Link pending
embi-20210331_cal.xml Edgar Link unprocessable
embi-20210331_def.xml Edgar Link unprocessable
embi-20210331_htm.xml Edgar Link completed
embi-20210331_lab.xml Edgar Link unprocessable
embi-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skye-20210331xex101.htm Edgar Link pending
skye-20210331xex101001.jpg Edgar Link pending
skye-20210331xex101002.jpg Edgar Link pending
skye-20210331xex311.htm Edgar Link pending
skye-20210331xex312.htm Edgar Link pending
skye-20210331xex321.htm Edgar Link pending
skye-20210331xex322.htm Edgar Link pending